HUMAN CENTRIC DRUG DISCOVERY

Putting human data at the centre of drug discovery

Embryonic Stem Cells
 
Pipetting Samples

WHO WE ARE

We are an Oxford University spin-out improving neurology drug discovery by bringing more human data to the process. We are experts in developing, analysing and combining data from induced pluripotent stem cells, large scale genetics studies, and population health data. We identify and validate safe and effective drug targets for neurological diseases where current models aren't working. We work with pharmaceutical partners and on in-house programmes. We are backed by the major venture capital fund Oxford Science Enterprises.

 
Human Centric 0011_edited_edited.png
Human Centric 0008.JPG
Human Centric 0007_edited.jpg

JAMES PEACH

Co-Founder and CEO

PROFESSOR ZAM CADER

Co-Founder and CSO

PROFESSOR
CALEB WEBBER

Co-Founder and CTO

 
Male Scientist

OUR TECHNOLOGY

Our approach combines three key technologies: genetically validated IPSC models that replicate disease states, genomic analysis showing the impact of disease and treatments across relevant tissue and patient groups, and retrospective analysis of population prescription and health data to illustrate safe and effective off-target impact.

 

JOB OPPORTUNITIES

HCDD is hiring operational, laboratory and data science roles - please find details below

Person Analyzing Data

DATA SCIENTIST

Details soon
Laboratory Scientist

RESEARCH SCIENTIST